GlassScriptPhysician profile
Emma Kerr
NPI 1891562864
$1,666.34
in general payments reported to CMS, 2019-2025
16 companies · $1,083 in 2025
The $1,083 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $584 · 2025: $1,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,587 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,587.35 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $452.25 | 2024-2025 | |
| Glaxosmithkline, LLC. | $396.57 | 2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $266.24 | 2024-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $142.00 | 2024 | Tezspire, Breztri, Airsupra |
| Philips North America LLC | $87.34 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Amgen INC. | $68.83 | 2024-2025 | Tezspire |
| Genentech USA, INC. | $32.04 | 2024 | Xolair |
| United Therapeutics Corporation | $28.83 | 2024-2025 | Tyvaso, Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $18.19 | 2024 | Aralast |
| Verona Pharma, INC. | $17.53 | 2025 | Ohtuvayre |
| Ani Pharmaceuticals, INC. | $17.25 | 2025 | Purified Cortrophin Gel |
| Optinose US, INC. | $16.83 | 2024 | |
| Avadel Cns Pharmaceuticals, LLC | $15.13 | 2024 | Lumryz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.52 | 2024 | Ofev |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $13.80 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Kerr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.